The proposed clinical trial shall address whether aspirin has utility in the prevention of lung adenocarcinoma. It is a phase IIb randomized placebo controlled, double blind trial of aspirin 100 mg per day given for 1 year to current and former smokers participating in helical CT screening trials at the European Institute of Oncology in Milan, Italy. The goal is to determine if low dose aspirin affects the size of non-solid or partially solid persistent lung nodules identified by CT, since a subset of these nodules represent precursors to lung cancer. The clinical trial shall be performed at the European Institute of Oncology, with monitoring and oversight provided by MD Anderson.

Agency
National Institute of Health (NIH)
Type
Station Support Contracts (N03)
Project #
261201200034I-0-26100002-1
Application #
8762957
Study Section
Project Start
2013-09-20
Project End
2016-09-19
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$1,094,406
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030